Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation
NCT01252784 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2010-12-03
Summary
The purpose of this study is to evaluate the feasibility and efficacy of reduced-intensity conditioning allogeneic HCT followed by prophylactic dose-escalating DLIs in patients with higher risk MDS.
Conditions
Sponsors & Collaborators
-
Cooperative Study Group A for Hematology
lead NETWORK
Principal Investigators
-
Je-Hwan Lee, Doctor · Asan Medical Center
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2012-10-31
- Completion
- 2014-10-31
Countries
- South Korea
Study Locations
More Related Trials
-
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS
NCT02969980 ·Status: COMPLETED ·Phase: PHASE2
-
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
NCT00025662 ·Status: COMPLETED ·Phase: PHASE2
-
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
NCT01518153 ·Status: TERMINATED ·Phase: PHASE2
-
Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome
NCT03643042 ·Status: TERMINATED ·Phase: NA
-
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
NCT00374933 ·Status: COMPLETED ·Phase: PHASE1
-
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
NCT00186576 ·Status: COMPLETED ·Phase: NA
-
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
NCT00185796 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
NCT01020734 ·Status: COMPLETED ·Phase: PHASE2
-
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
NCT04151706 ·Status: COMPLETED ·Phase: PHASE2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
NCT05805605 ·Status: RECRUITING ·Phase: PHASE2
-
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT06859424 ·Status: RECRUITING ·Phase: PHASE2
-
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
NCT06529731 ·Status: RECRUITING ·Phase: PHASE2
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
NCT07285668 ·Status: SUSPENDED ·Phase: NA
-
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
NCT00627666 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome
NCT00732316 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
NCT06892223 ·Status: RECRUITING ·Phase: PHASE2
-
Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT
NCT00774527 ·Status: COMPLETED ·Phase: PHASE3
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
NCT01174108 ·Status: RECRUITING ·Phase: PHASE2
-
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
NCT00047268 ·Status: UNKNOWN ·Phase: PHASE3
-
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
NCT00068718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant
NCT01627275 ·Status: COMPLETED ·Phase: PHASE1
-
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes
NCT01674985 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
NCT00004878 ·Status: WITHDRAWN ·Phase: PHASE2
-
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
NCT00860574 ·Status: COMPLETED ·Phase: PHASE2
-
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
NCT00080925 ·Status: COMPLETED ·Phase: PHASE1